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patients who survive for 30 days do remarkably well and during the next 9 years, 53%
remain alive. Readily available baseline characteristics identify patients at increased risk
for late mortality.
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815-3 Long-Term Survivors of Cardiogenic Shock Enjoy Good 
Functional Capacity, and a Strategy of Early 
Revascularization Is Protective Against Functional 
Class Deterioration and Death
Krishnan Ramanathan, Lynn A. Sleeper, Michael H. Picard, Harvey D. White, Thierry H. 
LeJemtel, Vladimir Dzavik, Deborah Tormey, Nancy E. Avis, Judith S. Hochman, New 
York University School of Medicine, New York, NY
Background: A strategy of emergency revascularization (ERV) in patients with cardio-
genic shock (CS) complicating an acute myocardial infarction (MI) improves 12-month
survival compared to initial medical stabilization with possible delayed revascularization
(IMS). Due to the critical nature of CS patients pre-revascularization, it is unclear whether
this survival benefit is associated with good or poor functional class and quality of life
(QOL)
Methods: Our study cohort (n=126) was patients with at least one phone interview at 2-
weeks post discharge (baseline), 6 and 12-months post-MI. Data were collected for a
predefined secondary endpoint of the SHOCK trial using standardized instruments.
Results: At 1-year post-MI 87% of survivors were in NYHA I/II. The QOL score and the
distributions of NYHA functional class (FC) were similar in the 2 treatment assignments
at all time points (p>0.1). The proportion of patients at 1-year with improvement in FC
was similar in the 2 treatment groups (18% overall), in the IMS group fewer remained sta-
ble (44% vs.71%) and more deteriorated or died (34% vs.15%). Proportion of patients in
NYHA I/II at 2- week (baseline) and 1-year was similar (67% and 71%), in contrast the
NYHA III/IV patients decreased (23% and 11%) due to deaths, significantly more in the
IMS group (treatment group comparison of NYHA I/II vs. III/IV vs. Death: p<0.036 for 6
and 12-months post-MI). Univariate correlates of a good outcome (not developing NYHA
III/IV or Death) at 1-year post-MI were treatment assignment to ERV and NYHA I/II at
baseline (p<0.046 for both).Only treatment assignment to ERV was significant in a multi-
variate model for good outcome at 1-year post-MI OR=0.31 ( 95%CI 0.13-0.76, p=0.01).
Conclusion: Patients who initially survive cardiogenic shock have good long-term sur-
vival with high functional capacity. Patients assigned to ERV have a lower rate of deterio-
ration in FC than IMS patients. A strategy of ERV is an independent strong predictor of 1-
year post-MI survival with good FC. ERV in the acute setting is a superior strategy with
respect to 1-year post MI survival and FC.
2:45 p.m.
815-4 Impact of an Open Artery Late After Infarction: 
Angiographic Results of the DECOPI Randomized Trial
Philippe Gabriel Steg, Christophe Thuaire, Dominique Himbert, Jacques Puel, S. 
Champagne, Damien Coisne, Khalife Khalife, Pierre Cazaux, Damien Logeart, Michel 
Slama, Sylvie Chevret, Lionel Brucker, for the DECOPI investigators, Hopital Bichat, 
Paris, France
Background: the value of late recanalization of the infarct vessel after myocardial infarc-
tion beyond the time window compatible with myocardial salvage remains debated
Method: DECOPI is a randomized trial enrolling patients with angiographically-proven
occlusion of the infarct vessel 2 to 15 days after onset, randomized to angioplasty or
medical therapy. Left ventricular and coronary angiography were repeated at 6 months.
Follow-up was clinical for 2 years. The primary endpoint was combined cardiovascular
death, non fatal myocardial infarction and ventricular tachyarrythmias.
Results: 212 patients were randomized. In the angioplasty arm, 80.4% of the patients
had placement of a stent and 9.4% a GpIIb/IIIa blocker. TIMI 3 flow was reestablished in
82% of the patients at the end of the procedure. After a mean follow-up of 34 months,
there was no difference in the primary endpoint between angioplasty and medical ther-
apy (7.3 vs8.7%, NS). At 6 month angiography, the infarct artery was patent in 82.7% vs
32.7% in the angioplasty and medical groups respectively (p<0.0001). However, there
was a 12% reocclusion and a 47% restenosis rate in the angioplasty arm and a 32%
spontaneous recanalisation rate in the medical arm. Left ventricular ejection fraction was
3.5% higher in the angioplasty arm (p=0.025).
When patients are categorized on the basis of patency at 6-month, independently of ran-
domization, patients with a patent infarct artery have markedly improved outcomes: lower
subsequent mortality 1% vs 9.1% (p=0.032), 6% higher left ventricular ejection fraction
(p=0.004) and a trend towards a lower incidence of the primary endpoint (2% vs 6.1%,
p=0.18)
Conclusion: These results suggest that there is little clinical benefit to routine late reca-
nalization of the infarct artery. However, recanalization is associated with improved ejec-
tion fraction. Patients with a patent vessel at 6-months appear to fare substantially better
than patients with occlusion. This suggests that prevention of reocclusion and restenosis
are key to the clinical benefit of late recanalization.
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815-5 Long-Term Results of Primary Nonfacilitated 
Percutaneous Coronary Intervention in Acute 
Myocardial Infarction Patients Transferred for Up to 100 
Kilometers: Results of a Real-Life Registry
Maciej Karcz, Pawel Bekta, Cezary Kepka, Ewa Ksiezycka, Andrzej Ciszewski, Zbigniew 
Chmielak, Marcin Demkow, Artur Debski, Michal Ciszewski, Adam Witkowski, Witold 
Ruzyllo, National Institute of Cardiology, Warsaw, Poland
Background: Concern remains as to whether benefit of primary percutaneous coronary
intervention (pPCI) is not abolished by treatment delay in patients (pts) with acute myo-
cardial infarction (AMI) who have to be transferred for pPCI to an invasive center from
community hospitals.
Methods: A prospective registry of consecutive unselected patients treated with pPCI
within 12 hours of AMI in a single very high-volume tertiary center was interrogated.
Before/during transport patients were pretreated with aspirin and usually heparin but not
with fibrinolytics or glycoprotein receptor inhibitors. Long-term survival was established
by telephone contact and through National Death Registry.
Results: From 02/2001 through 01/2002 pPCI was performed in 602 pts including 457
pts transferred from community hospitals (transfer distance ranged 3-100 kilometers
(kms), exceeded 30 kms in 40% pts). Transferred pts did not differ significantly from non-
transferred patients with the exception of older age (61 vs. 54 years, p=0.02), longer time
from onset of pain to admission to our center (3.2 vs. 2.2 hours, p=0.0005), and lower
incidence of shock on admission (3% vs. 9%). The overall incidence of “not-low-risk”
characteristics was the same (70%) Rates of stenting (75% transferred vs. 82% non-
transferred) and abciximab use in cathlab (48% vs. 53%) were high and comparable in
both groups. TIMI 3 flow was achieved in 83% and 85% pts after pPCI, respectively (NS).
One-year follow up was 100% complete. Mortality was similar in transferred and non-
transferred pts (6% and 7%, respectively).
Conclusion: Patients with AMI transferred from distant hospitals for up to 100 kms for
non-facilitated primary coronary intervention have good one-year survival (similar to that
of patients originally admitted to an invasive center) even though transport to an invasive
center results in treatment delay.
3:15 p.m.
815-6 Prognostic Effect of Left Bundle Brunch Block on 
Presenting Electrocardiogram in Patients With Acute 
Myocardial Infarction Treated With Primary Angioplasty 
in the Primary Angioplasty in Myocardial Infarction 
Trials
Mayra Guerrero, Kishore Harjai, Judy Boura, Cindy Grines, William Beaumont Hospital, 
Royal Oak, MI
Background: The presence of left bundle brunch block (LBBB) has been associated with
poor outcomes in patients with myocardial infarction (MI). Whether this is true in the
angioplasty era is not known. We sought to evaluate the outcome of patients with acute
MI and LBBB on initial electrocardiogram (EKG) treated with primary angioplasty.
Methods: We evaluated 1,483 patients who were randomized to primary angioplasty for
the treatment of acute MI in the Primary Angioplasty in Myocardial Infarction (PAMI) trials
and had information about the presence or absence of LBBB on presenting EKG.
Patients with LBBB (n=39, 2.6%) on presenting EKG were compared to patients with ST
segment elevation.
Results: Patients with LBBB were older (69 vs 61 years, p<0.0001), had more frequent
history of hypertension (62% vs 45%, p=0.038), prior coronary artery bypass surgery
(10% vs 3.4%, p=0.048), they presented more often with Killip class >1 (20.5% vs 9.7%,
p=0.050), and had more multivessel disease (64% vs 50%, p=0.013). There was no sig-
nificant difference in initial or final TIMI (Thrombolysis in MI) flow, use of stent, left ante-
rior descending infarct related artery, or ejection fraction. The incidence of in-hospital
major adverse cardiac events (MACE) including death, ischemic target vessel revascular-
ization (I-TVR) and reinfarction, tended to be higher in patients with LBBB (13% vs 5.5%,
p=0.068) due primarily to significant increased in-hospital death (10% vs 3.1%, p=0.035).
In multivariate logistic regression analysis, LBBB was an independent predictor of in-hos-
pital death after adjusting for other variables (odds ratio 4.04, 95% confidence interval
0.99-16.4, p=0.05).
Conclusions: Patients with acute MI and LBBB on presenting EKG have increased
MACE and mortality despite treatment with primary angioplasty. The presence of LBBB
was an independent predictor of in-hospital death.
